Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancers|July 24, 2021
Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid LeukemiaAxel H Schönthal, Steve Swenson, Radu O Minea, et al.Oncotarget|January 18, 2019
NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivoSteve Swenson, Catalina Silva-Hirschberg, Weijun Wang, et al.Therapeutic Advances in Medical Oncology|December 17, 2019
Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitroCatalina Silva-Hirschberg, Hannah Hartman, Samantha Stack, et al.Journal of Neurosurgery. Case Lessons|September 11, 2022
Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative caseAxel H Schönthal, Steve Swenson, Phillip A Bonney, et al.International Journal of Cancer|July 23, 2014
NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancerKate Lawrenson, Barbara Grun, Nathan Lee, et al.Journal of Neurosurgery|December 31, 2005
Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapyWeijun Wang, Nian-Ling Zhu, Jason Chua, et al.Journal of Economic Entomology|April 22, 2024
Developing semiochemical repellents for protecting Picea from Dendroctonus rufipennis (Coleoptera: Curculionidae) in Alaska and Utah, USAJackson P Audley, Christopher J Fettig, Jason E Moan, et al.Neuro-Oncology Advances|January 4, 2021
Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in miceHee-Yeon Cho, Steve Swenson, Thu Zan Thein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortiaAgustin A Garcia, Hal Hirte, Gini Fleming, et al.Pageof 2